Antibody-Based Imaging of HER-2: Moving into the Clinic

Title:Antibody-Based Imaging of HER-2: Moving into the Clinic

Volume: 13 Issue: 10

Author(s): R. E. Wang, Y. Zhang, L. Tian, W. Cai and J. Cai

Affiliation:

Keywords: Antibody, drug delivery, magnetic resonance imaging (MRI), near-infrared fluorescence (NIRF) imaging, photoacoustic tomography (PAT), positron emission tomography (PET), radioimmunoscintigraphy (RIS), singlephoton emission computed tomography (SPECT).

Abstract: Human epidermal growth factor receptor-2 (HER-2) mediates a number of important cellular activities, and is up-regulated in a diverse set of cancer cell lines, especially breast cancer. Accordingly, HER-2 has been regarded as a common drug target in cancer therapy. Antibodies can serve as ideal candidates for targeted tumor imaging and drug delivery, due to their inherent affinity and specificity. Advanced by the development of a wide variety of imaging techniques, antibody-based imaging of HER-2 can allow for early detection and localization of tumors, as well as monitoring of drug delivery and tissue’s response to drug treatment. In this review article, antibody-based imaging of HER-2 are summarized and discussed, with an emphasis on the involved imaging methods.

Cite this article as:

Wang E. R., Zhang Y., Tian L., Cai W. and Cai J., Antibody-Based Imaging of HER-2: Moving into the Clinic, Current Molecular Medicine 2013; 13(10) . https://dx.doi.org/10.2174/1566524013666131111120951